Phosphodiesterase inhibitors for pulmonary hypertension

New England Journal of Medicine

Volumn 362, Issue 6, 2010, Pages 559-560

  Bergot, Emmanuel ^a   Magnier, Romain ^a   Zalcman, Gérard ^a  

^a CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; VASODILATOR AGENT; CARBOLINE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SILDENAFIL; SULFONE; TADALAFIL; BOSENTAN;

CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ERROR; HEART LEFT VENTRICLE FAILURE; LETTER; LUNG TRANSPLANTATION; OPEN LUNG BIOPSY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; RADIOLOGY; THORAX; DRUG ANTAGONISM; EVIDENCE BASED MEDICINE; HUMAN; META ANALYSIS; NOTE; INOTROPISM; MEDICAL SOCIETY; MORTALITY; PHYSICIAN; PRACTICE GUIDELINE; PUBLICATION; RECOMMENDED DRUG DOSE;

CARBOLINES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION, PULMONARY; META-ANALYSIS AS TOPIC; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; SULFONES;

EID: 76649098345     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc0912127     Document Type: Letter

References (4)

1. Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med 2009;361:1864-71.
2. Montani D, Achouh L, Dorfmüller P, et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008;87:220-3.
3. Montani D, Price LC, Dorfmüller P, et al. Pulmonary veno-occlusive disease. Eur Respir J 2009;33:189-200.
4. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-30.